Single-dose liposomal amphotericin B for visceral leishmaniasis in India

New England Journal of Medicine

Volumn 362, Issue 6, 2010, Pages 504-512

  Sundar, Shyam ^a   Chakravarty, Jaya ^a   Agarwal, Dipti ^a   Rai, Madhukar ^a   Murray, Henry W ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY GLUCONATE; CHLORPHENIRAMINE; MILTEFOSINE; PARACETAMOL; PAROMOMYCIN;

ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL PNEUMONIA; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG COST; DRUG EFFICACY; FEMALE; FEVER; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPOKALEMIA; INDIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OPEN STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SCHOOL CHILD; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS;

EID: 76649099805     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0903627     Document Type: Article

References (21)

1. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005;366:1561-77.
2. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002;66:143-6.
3. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004;38:377-83.
4. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001;323:419-22.
5. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003;37:800-4.
6. Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008;47:1000-6.
7. Berman J. ABLE: a new and improved amphotericin B for visceral leishmaniasis? Am J Trop Med Hyg 2009;80:689-90.
8. Olliaro P, Darley S, Laxminarayan R, Sundar S. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009;14:918-25.
9. Sundar S, Chakravarty J, Rai VK, et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 2007;45:556-61.
10. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356:2571-81.
11. Common Terminology Criteria for Adverse Events (CTCAE). Bethesda, MD: National Cancer Institute, 2006. (Accessed January 15, 2010, at https://webapps .ctep.nci.nih.gov/webobjs/ctc/webhelp/ Common-Terminology-Criteria-for- Adverse-Events-CTCAE-v3.htm.)
12. Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 2001;17:67-70.
13. Syriopoulou V, Daikos GL, Theodori dou M, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003;36:560-6.
14. Murray HW. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2004;2:279-92. [Erratum, Expert Rev Anti Infect Ther 2004;2:462.]
15. Sundar S, Thakur BB, Tandon AK, et al. Clinicoepidemiological study of drug resistance in Indian kala-azar. BMJ 1994;308:307.
16. Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007;196:591-8.
17. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46.
18. Mondal D, Singh SP, Kumar N, et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 2009;3(1):e355.
19. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005;83:394-5.
20. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45:3487-96.
21. Adler-Moore J, Proffitt RT. Effect of tissue penetration on AmBisome efficacy. Curr Opin Investig Drugs 2003;4:179-85.